BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

Q: What is BMRN’s average 12-month price target, according to analysts?

Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 98.59.

Q: What is BMRN’s upside potential, based on the analysts’ average price target?

BioMarin Pharmaceutical has 82.78% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is BMRN a Buy, Sell or Hold?

BioMarin Pharmaceutical has a consensus rating of Strong Buy which is based on 20 buy ratings, 4 hold ratings and 0 sell ratings.

Q: What is BioMarin Pharmaceutical’s price target?

The average price target for BioMarin Pharmaceutical is 98.59. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $122.00 ,the lowest forecast is $60.00. The average price target represents 82.78% Increase from the current price of $53.94.

Q: What do analysts say about BioMarin Pharmaceutical?

BioMarin Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.

Q: How can I buy shares of BMRN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

2,277 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BMRN Analyst Ratings

Strong Buy

20 Buy

4 Hold

0 Sell

Based on 24 analysts giving stock ratings to

BioMarin

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BMRN Stock 12 Month Forecast

Average Price Target

$98.59

▲(82.78% Upside)

Based on 24 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $98.59 with a high forecast of $122.00 and a low forecast of $60.00. The average price target represents a 82.78% change from the last price of $53.94.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"55":"$55","72":"$72","89":"$89","106":"$106","123":"$123"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$122.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":98.59,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$98.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[55,72,89,106,123],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.09,63.92923076923077,68.76846153846154,73.6076923076923,78.44692307692307,83.28615384615384,88.12538461538462,92.96461538461539,97.80384615384615,102.64307692307692,107.48230769230769,112.32153846153847,117.16076923076923,{"y":122,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.09,62.12846153846154,65.16692307692308,68.20538461538462,71.24384615384616,74.2823076923077,77.32076923076923,80.35923076923078,83.39769230769231,86.43615384615384,89.47461538461539,92.51307692307692,95.55153846153846,{"y":98.59,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.09,59.160000000000004,59.230000000000004,59.300000000000004,59.370000000000005,59.440000000000005,59.510000000000005,59.58,59.65,59.72,59.79,59.86,59.93,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":91.21,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.94,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.09,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$122.00

Average Price Target$98.59

Lowest Price Target$60.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Christopher Raymond

Raymond James

$85

Buy

57.58%

Upside

Reiterated

09/17/25

Raymond James Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Sami Corwin

William Blair

―

Hold

―

Reiterated

09/08/25

BioMarin Pharmaceutical (BMRN) Receives a Hold from William Blair

Yun Zhong

Wedbush

$94

Buy

74.27%

Upside

Reiterated

09/08/25

BioMarin Pharmaceutical's Growth Potential: Promising Phase 3 Data, Revenue Growth, and Strategic Initiatives Support Buy Rating

Mitchell Kapoor

H.C. Wainwright

$60

Hold

11.23%

Upside

Initiated

09/08/25

BioMarin initiated with a Neutral at H.C. WainwrightBioMarin initiated with a Neutral at H.C. Wainwright

Kostas Biliouris

BMO Capital

$115

Buy

113.20%

Upside

Reiterated

09/07/25

BioMarin Pharmaceutical: Promising Growth with Palynziq Expansion and Robust Product Pipeline

Sean Laaman

Morgan Stanley

$104

Buy

92.81%

Upside

Reiterated

09/04/25

Morgan Stanley Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)Biomarin Pharmaceutical Inc is rated Overweight with a consistent price target of 104.00.

Leland Gershell

Oppenheimer

$98

Buy

81.68%

Upside

Reiterated

08/26/25

Oppenheimer Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $98.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).

William Pickering

Bernstein

$94→$95

Buy

76.12%

Upside

Reiterated

08/19/25

Bernstein Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)Bernstein SocGen Group analyst William Pickering raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $95.00 (from $94.00) while maintaining an Outperform rating.

Gena Wang

Barclays

$86

Buy

59.44%

Upside

Reiterated

08/13/25

BioMarin Pharmaceutical (BMRN) Receives a Buy from Barclays

Cory Kasimov

Evercore ISI

$110

Buy

103.93%

Upside

Reiterated

08/11/25

Evercore ISI Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Jason Gerberry

Bank of America Securities

$103

Buy

90.95%

Upside

Reiterated

08/08/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Globus Medical (NYSE: GMED) and BioMarin Pharmaceutical (NASDAQ: BMRN)We maintain Buy and see internal/external de-risking milestones for BMRN’s skeletal dysplasia business as largely upside to the stock.

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/06/25

Truist Financial Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

Debjit Chattopadhyay

Guggenheim

$101→$106

Buy

96.51%

Upside

Reiterated

08/06/25

BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim

Joseph Schwartz

Leerink Partners

$105

Buy

94.66%

Upside

Reiterated

08/05/25

Positive Outlook on BioMarin Pharmaceutical: Strong Financials and Promising Pipeline Drive Buy Rating

Jessica Fye

J.P. Morgan

$113→$116

Buy

115.05%

Upside

Reiterated

08/05/25

Positive Outlook for BioMarin Pharmaceutical Driven by Strong Financial Performance and Growth Opportunities

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Christopher Raymond

Raymond James

$85

Buy

57.58%

Upside

Reiterated

09/17/25

Raymond James Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Sami Corwin

William Blair

―

Hold

―

Reiterated

09/08/25

BioMarin Pharmaceutical (BMRN) Receives a Hold from William Blair

Yun Zhong

Wedbush

$94

Buy

74.27%

Upside

Reiterated

09/08/25

BioMarin Pharmaceutical's Growth Potential: Promising Phase 3 Data, Revenue Growth, and Strategic Initiatives Support Buy Rating

Mitchell Kapoor

H.C. Wainwright

$60

Hold

11.23%

Upside

Initiated

09/08/25

BioMarin initiated with a Neutral at H.C. WainwrightBioMarin initiated with a Neutral at H.C. Wainwright

Kostas Biliouris

BMO Capital

$115

Buy

113.20%

Upside

Reiterated

09/07/25

BioMarin Pharmaceutical: Promising Growth with Palynziq Expansion and Robust Product Pipeline

Sean Laaman

Morgan Stanley

$104

Buy

92.81%

Upside

Reiterated

09/04/25

Morgan Stanley Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)Biomarin Pharmaceutical Inc is rated Overweight with a consistent price target of 104.00.

Leland Gershell

Oppenheimer

$98

Buy

81.68%

Upside

Reiterated

08/26/25

William Pickering

Bernstein

$94→$95

Buy

76.12%

Upside

Reiterated

08/19/25

Gena Wang

Barclays

$86

Buy

59.44%

Upside

Reiterated

08/13/25

BioMarin Pharmaceutical (BMRN) Receives a Buy from Barclays

Cory Kasimov

Evercore ISI

$110

Buy

103.93%

Upside

Reiterated

08/11/25

Evercore ISI Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Jason Gerberry

Bank of America Securities

$103

Buy

90.95%

Upside

Reiterated

08/08/25

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/06/25

Truist Financial Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

Debjit Chattopadhyay

Guggenheim

$101→$106

Buy

96.51%

Upside

Reiterated

08/06/25

BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim

Joseph Schwartz

Leerink Partners

$105

Buy

94.66%

Upside

Reiterated

08/05/25

Positive Outlook on BioMarin Pharmaceutical: Strong Financials and Promising Pipeline Drive Buy Rating

Jessica Fye

J.P. Morgan

$113→$116

Buy

115.05%

Upside

Reiterated

08/05/25

Positive Outlook for BioMarin Pharmaceutical Driven by Strong Financial Performance and Growth Opportunities

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

1 Month

xxx

Success Rate

15/27 ratings generated profit

Average Return

<+0.01%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of <+0.01% per trade.

3 Months

xxx

Success Rate

15/36 ratings generated profit

Average Return

-0.32%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -0.32% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

20/45 ratings generated profit

Average Return

-3.92%

reiterated a buy rating last month

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -3.92% per trade.

2 Years

xxx

Success Rate

9/25 ratings generated profit

Average Return

-9.81%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 36.00% of your transactions generating a profit, with an average return of -9.81% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMRN Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BMRN has received 46 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the past 3 months is 98.59.

Each month's total comprises the sum of three months' worth of ratings.

BMRN Financial Forecast

BMRN Earnings Forecast

Next quarter’s earnings estimate for BMRN is $0.88 with a range of $0.65 to $1.18. The previous quarter’s EPS was $1.23. BMRN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.

BMRN Sales Forecast

Next quarter’s sales forecast for BMRN is $789.12M with a range of $769.81M to $822.00M. The previous quarter’s sales results were $827.47M. BMRN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.39% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.

BMRN Stock Forecast FAQ

What is BMRN’s average 12-month price target, according to analysts?

Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 98.59.

What is BMRN’s upside potential, based on the analysts’ average price target?

BioMarin Pharmaceutical has 82.78% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BMRN a Buy, Sell or Hold?

BioMarin Pharmaceutical has a consensus rating of Strong Buy which is based on 20 buy ratings, 4 hold ratings and 0 sell ratings.

What is BioMarin Pharmaceutical’s price target?

The average price target for BioMarin Pharmaceutical is 98.59. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $122.00 ,the lowest forecast is $60.00. The average price target represents 82.78% Increase from the current price of $53.94.

What do analysts say about BioMarin Pharmaceutical?

BioMarin Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of BMRN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BMRN Analyst Ratings

BMRN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioMarin Pharmaceutical

BMRN Analyst Recommendation Trends

BMRN Financial Forecast

BMRN Earnings Forecast

BMRN Sales Forecast

BMRN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts